SCHEMBL22917293

SCHEMBL22917293

CNC(=O)C1CCN(C(=O)C(C)C)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
ALDH1A1 P00352 3/20 0.47
GAA P10253 1/20 0.43
HSD17B10 Q99714 1/20 0.42
CASP3 P42574 1/20 0.41
CHRNB2 P17787 1/20 0.39
CHRNA3 P32297 1/20 0.39
CHRNA4 P43681 1/20 0.39
CHRNB3 Q05901 1/20 0.39
CHRNA6 Q15825 1/20 0.39
EPHX2 P34913 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C19 P33261 1/20 0.39
PTPN1 P18031 1/20 0.38
NAMPT P43490 1/20 0.38
CYP2D6 P10635 1/20 0.38
HRH3 Q9Y5N1 1/20 0.38
TRPV1 Q8NER1 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28644292 0.86 ALDH1A1 (0.61) SMN1; SMN2MEN1KMT2AALDH1A1GAA
SCHEMBL22916980 0.84 KMT2A (0.68) SMN1; SMN2MEN1KMT2AALDH1A1GAA
SCHEMBL28185381 0.84 MEN1 (0.46) SMN1; SMN2MEN1KMT2AALDH1A1GAA
SCHEMBL23011801 0.81 CHRNB2 (0.50) SMN1; SMN2MEN1KMT2AALDH1A1GAA
SCHEMBL13332897 0.80 HSD17B10 (0.51) SMN1; SMN2MEN1KMT2AGAAHSD17B10
SCHEMBL1034955 0.79 SMN1; SMN2 (0.54) SMN1; SMN2MEN1KMT2AALDH1A1GAA
SCHEMBL8351549 0.79 SMN1; SMN2 (0.50) SMN1; SMN2MEN1KMT2AALDH1A1HSD17B10
SCHEMBL16643864 0.79 MEN1 (0.50) SMN1; SMN2MEN1KMT2AALDH1A1GAA
SCHEMBL322431 0.79 LMNA (0.50) MEN1KMT2AALDH1A1GAACHRNB2
SCHEMBL12531876 0.79 MEN1 (0.46) SMN1; SMN2MEN1KMT2AALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159554-A1 COMPOUND WITH ANTICANCER ACTIVITY KYOWA KIRIN CO., LTD. (JP) 2023-05-25 US disclosed
US-20210024540-A1 COMPOUND WITH ANTICANCER ACTIVITY KYOWA KIRIN CO., LTD. (JP) 2021-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210024540-A1 COMPOUND WITH ANTICANCER ACTIVITY TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC2 SMN1; SMN2 376/4885MEN1 41/4885KMT2A 2349/4885
US-20230159554-A1 COMPOUND WITH ANTICANCER ACTIVITY TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC2 SMN1; SMN2 376/4885MEN1 41/4885KMT2A 2349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.